Original editorial analysis: pricing math, regulatory explainers, clinical evidence, transparency analysis, and honest tradeoffs in the compounded semaglutide telehealth market. 10 articles, monthly updates.
Standard semaglutide titration takes 16-20 weeks to reach maintenance dose. We work the math on a $99 first-month offer vs flat-rate, and why the 12-month delta is typically $900-$1,800.
503A and 503B compounding pathways operate under different federal frameworks. We explain what each means for sterility QC, batch testing, prescription requirements, and your safety profile.
Six weeks after the FDA's April 14 framework targeting compounded GLP-1 medications, what's actually changed for patients. The framework, the enforcement targets, and what compliant providers look like.
Of 25 directory providers, only one publicly discloses all six named partner pharmacies pre-purchase. Why this single transparency item carries 22% of our six-pillar score.
STEP-1 showed ~15% weight loss at 68 weeks with brand-name semaglutide 2.4 mg. SELECT showed 20% cardiovascular event reduction. What these trials mean for compounded semaglutide outcomes.
Brand-name Wegovy/Ozempic is FDA-approved with extensive clinical-trial backing. Compounded semaglutide is not. We walk through the patient-by-patient decision logic.
Pharmacy disclosure, dose-tier pricing, medical director credentials, included support, cancellation terms. The five-minute pre-signup interview that protects you from the worst telehealth tier.
Many telehealth providers list 'patient support included' without specifying what's bundled. We define what included support should cover, and how Care360 compares.
Most semaglutide telehealth comparison content stops at the first-month price. We show the full 12-month math on NexLife, Henry Meds, Mochi, Hims, and Ro Body.
If compounded is so much cheaper, why isn't everyone on it? The honest tradeoffs — not FDA-approved, formula variability, regulatory uncertainty — and how to evaluate whether they apply to you.
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.